baber/WOPTO huggingface dataset:
Patent CA-2339286-A1 (CA)
Title: New compounds
Inventor: AMIN KOSRAT
IPC: C07D471/04
Filed: 1999-08-18
Abstract: The present invention relates to novel compounds, and therapeutically acceptable salts thereof of formula (I), which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.
Patent CA-2341389-A1 (CA)
Title: Casket lid and method of making same
Inventor: SAAF PATRICK M
IPC: A61G17/007
Filed: 1999-09-08
Abstract: A method of making a one-piece, unitary lid for a casket comprises pro-viding tooling configured to produce a casket lid having a crown, a pie, a rim and a header, providing settable material, preferably a mixture of wood chips and binder, from which to mold the lid, mold-ing the settable material with the tooling and permitting the settable material to set.  The tooling transmits a wood grain pat-tern into the settable material. The wood grain pattern of the lid is continuous when viewed rotated 180° about an axis perpen-dicular to the plane defined by the lid, lo-cated medially of the transverse extent of the lid and coinciding with the header end edge of the lid. Thus two such caps placed end-to-end have a continuous wood grain pattern extending from the head end of the casket to the foot end of the casket. Resin impregnated tissue paper is applied to the settable material prior to molding. The resin impregnated tissue paper conforms to the wood grain and conceals the wood chips.
Patent CA-2341921-A1 (CA)
Title: Amide compounds intermediates
Inventor: HASHIMOTO HIROMASA
IPC: C07D207/333
Filed: 1995-12-18
Abstract: Disclosed are amide compounds of the formula:    wherein R1" is   (in which R4, R5, R6 and R7 are each H, halo, alkyl, alkoxy, CF3, OH or NH2 provided that at least one of them is other than H); R" is cyclohexyl or 4-fluorophenyl and R2 is alkyl or haloalkyl). They are useful as intermediates for producing oxazole compounds of the formula:    wherein one of R and R1 is   (in which R3 is alkyl, amino or alkylamino and the other symbols are as defined above) and the other is cycloalkyl, heterocycle or aryl and R2 is as defined above, that are cyclooxygenase-2 (COX-2) inhibitors and are as useful as pharmaceuticals.
Patent CA-2343290-A1 (CA)
Title: A packaging container with an opening device, knife apparatus and method to produce said container
Inventor: PALMNAS MARKUS
IPC: B65D5/06
Filed: 1999-09-29
Abstract: The present invention relates to packaging containers (10) for pourable food products, comprising a laminated, tubular packaging material with opposed end fin portions (11, 12) that have been produced by sealing and cutting a continuous packaging material web between consecutive packages. A line (14) of perforations extends across a corner of one of the end portions (11) to facilitate the opening of the container. The cut edge of the end fin portion (11) with the line (14) of perforations is provided with a bend (11d), so that a first segment (11b) of the cut edge extends more close to the product-filled part (13) of the container than a second segment (11c) of the cut edge. The second segment (11c) of the cut edge which is more distant from the product-filled part of the container than the first segment, forms a grip-tab (11a) for opening the perforated corner.  The invention also relates to a knife apparatus and a method to produce the packaging container.
Patent CA-2351690-A1 (CA)
Title: Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing a substituted phenylenediamine group
Inventor: JONES THOMAS RICHARD
IPC: C07D277/20
Filed: 1999-12-06
Abstract: Compounds of formula (I) wherein R1-R5 are independently selected from hydrogen, or substituents R9-R12 are independently hydrogen, or substituents  provided that at least one of R9-12 is not hydrogen; G is a monocyclic heteroaryl: X is a bond, -NH, alkyl of 1 to 6 carbon atoms, alkenyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, or thioalkyl of 1 to 6 carbon atoms, alkylamino of 1 to 6 carbon atoms, or (CH)J; J is alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 7 carbon atoms, phenyl or benzyl, useful in  the treatment of diseases associated with herpes viruses including human cytomegalovirus, herpes simplex viruses, Epstein-Barr virus, varicella-zoste r virus, human herpesviruses-6 and -7, and Kaposi herpesvirus.
Patent CA-2352595-A1 (CA)
Title: Compositions comprenant au moins un autobronzant mono ou polycarbonyle et un compose du type sel de flavylium non substitue en position 3 pour la coloration de la peau et utilisations
Inventor: FORESTIER SERGE
IPC: A61K8/34
Filed: 2001-07-10
Abstract: La présente invention se rapporte à des compositions cosmétiques et/ou dermatologiques destinées à la coloration artificielle de la peau, caractérisée par le fait qu'elle comprend, dans un support cosmétiquement acceptable, au moins un autobronzant mono ou polycarbonylé et au moins un composé du type sel de flavylium, non substitué en position 3, et substitué par au moins un radical hydroxyle ou alcoxy, obtenu par voie de synthèse ou à partir d'un extrait végétal le contenant ou  bien encore à partir d'un extrait végétal enrichi le contenant.  L'invention concerne également les applications de ces compositions à la coloration de la peau.
Patent CA-2355845-A1 (CA)
Inventor: WEI YANGDOU
IPC: C12N15/54
Filed: 1999-12-16
Abstract: The present invention relates to the isolation, purification, characterization and use of the plant diacylglycerol acyltransferase (DGAT) gene and genetic products. For example, the invention provides DGAT cDNA [SEQ  ID NO:1] (pDGATcDNA; ATCC No PTA-989) and a plant diacylglycerol acyltransferase gene [SEQ ID NO:3] (pDGATgene; ATCC  No PTA-988) from the Brassicaceae (specifically Arabidopsis thaliana). The invention includes isolated and purified DGAT DNA, preferably of the stated sequences and homologues, and relates to methods of regulating seed oil content, the ratio of diacylglycerol/triacylglycerol proportions in the seed oil, fatty acid synthesis, seed oil acyl composition, seed size/weight and carbon flux into other seed components, using the gene, and to tissues and plants transformed with the gene. The invention also relates to transgenic plants, plant tissues and plant seeds having a genome containing an introduced DNA  sequence of the invention, and a method of producing such plants and plant seeds. The invention also relates to [SEQ ID NO:1] containing an 81 bp insertion [SEQ ID NO:23], and uses thereof to modify oil content, acyl composition of triacylglycerols, seed size or carbon flux into other seed components.
Patent CA-2357441-A1 (CA)
Title: Support for exhaustion recovery in a data processing system with memory mirroring
Inventor: BEALKOWSKI RICHARD
IPC: G06F11/20
Filed: 2001-09-18
Abstract: A memory exhaustion condition is handled in a data processing system having first and second regions of physical memory. The memory exhaustion condition is detected while the second region is mirroring at least part of the first region. In response to the memory exhaustion condition, memory mirroring is at least partially deactivated and at least part of the second region is utilized to augment the first region, such that the memory exhaustion condition is eliminated. In an illustrative embodiment, the data processing system compresses real memory into the first region of physical memory, and the memory exhaustion condition arises when the first region lacks sufficient available capacity to accommodate current requirements for real memory. The memory exhaustion condition is eliminated by compressing at least part of the real memory into the second region.
Patent CA-2359350-A1 (CA)
Inventor: CHEN JEFFREY W
IPC: B21D51/38
Filed: 2000-01-10
Abstract: A method and apparatus of forming a flange (14) in the bottom of a container (10) by first removing a portion of the container bottom (28) and then forming or swaying the material around the opening (28) to form a flange (14) extending away from the container bottom. A valve (24) and valve cup (22) assembly along with a heat exchange unit (16, 18, 32) are positioned adjacent the flange (14) and the combination is crimped to permanently affix the heat exchange unit (16, 18, 32) to the bottom of the container (12).
Patent CA-2360067-A1 (CA)
Title: Any-to-any component computing system
Inventor: LOWE STEVEN
IPC: G06F9/44
Filed: 2000-11-13
Abstract: A universal data and software structure and method for an Any-to-Any computing machine in which any number of any components can be related to any number of any other components in a manner that is not intrinsically hierarchical and is intrinsically unlimited. The structure and method includes a Concept Hierarchy; each concept or assembly of concepts is uniquely identified and assigned a number in a Numbers Concept Language or uniquely identified in a Non-numbers Concept Language. Each Component or assembly of Components is intrinsically related to all other data items that contain common or related components.
Patent CA-2361308-A1 (CA)
Inventor: FISHER PHILIP A
IPC: C08B37/00
Filed: 2000-02-15
Abstract: An entirely aqueous method for concentrating water soluble polysaccharides having molecular weights of at least about 50 kDa. The method comprises evaporating a water soluble polysaccharide-containing solution until surface film formation occurs, and harvesting the resulting film which is enriched in the polysaccharide. The polysaccharide may be of plant or animal origin, and includes polysaccharides such as guar gum, xanthan gum and pectin.
Patent CA-2366058-A1 (CA)
Title: Cdna molecules of the members of gene family encoding human fatty acid desaturases and their use in diagnosis and therapy
Inventor: WEBER BERNHARD H F
IPC: C12N9/12
Filed: 2000-03-07
Abstract: The present invention relates to the cloning and sequencing of the cDNA molecules of three members of a gene family encoding three human fatty acid desaturases, fatty acid desaturase-1 (FADS1), fatty acid desaturase-2 (FADS2 ) and fatty acid desaturase-3 (FADS3). The invention also relates to diagnosti c methods of screening for and detection of FADS1, FADS2, FADS3 and gene thera py utilizing recombinant DNA as well as the generation of animal models (knock- in, knock-out, transgenic animals), anti-FADS1, anti-FADS2, anti-FADS3 antibodies and use in screenings for modulating drugs.
Patent CA-2373909-A1 (CA)
Title: Multilayer drug form release in the colon
Inventor: PETEREIT HANS-ULRICH
IPC: A61P31/04
Filed: 2001-03-09
Abstract: The invention relates to the use of a multilayer pharmaceutical product that substantially comprises a) a core contain-ing a pharmaceutically active substance, h) an inner coating consisting of a copolymer or a mixture of copolymers that are composed of 85 to 98 wt.- % of radically polymerized C1 to C4 alkyl esters of the acrylic or methacrylic acid and 15 to 2 wt.- % of (meth)acrylate monomers with a quaternary ammonium group in the alkyl group, and c) an outer coating consisting of a copolymer that is composed of 75 to 95 wt.- % of radically polymerized C1 to C4 alkyl esters of the acrylic or methacrylic acid and 5 to 25 wt.- % of (meth)acry-late monomers with an anionic group in the alkyl group. The inventive product is used for producing a pharmaceutical product that releases the active substance contained therein according to the USP release test, at pH 1.2 during 2 hours and subsequent rebuffering to pH 7.0, by less than 5 % after 2.0 hours after start of the test aid by 30 to 80 % after eight hours after start of the test.
Patent CA-2376174-A1 (CA)
Title: Mid-wheel drive wheelchair with rigid front wheel anti-tip stabilizer
Inventor: JINDRA JOHN A
IPC: A61G5/10
Filed: 2000-06-28
Abstract: A mid-wheel drive wheelchair can have various suspensions for the drive whee l such as a rigid connection to the wheelchair frame or a resilient connection  thereto. The wheelchair has at least one anti-tip front wheel stabilizer, which is rigidly, i.e. non-resiliently, connected to the frame and according ly the wheelchair frame moves up and down with the anti-tip wheel upon encountering a bump, hill, etc. The height of the anti-tip wheel above the travel surface is adjustable and accordingly the wheel can be set to a specific height.
Patent CA-2379752-A1 (CA)
Inventor: GESSA GIAN LUIGI
IPC: A61P25/34
Filed: 2000-06-30
Abstract: The use of agonists of GABA B receptors and pharmaceutically acceptable derivatives thereof, in the therapy of maintaining nicotine abstinence in nicotine-dependant subjects, who intend to stop smoking, is herein described.
Patent CA-2380222-A1 (CA)
Title: Portable screening device and method
Inventor: WHITE KENNETH A
IPC: B06B1/16
Filed: 2002-04-03
Abstract: In combination, a dump truck mountable particle screener for mounting at op the dump body of a dump truck, and a dump truck. The dump-truck mountable particle screener has a support frame, a screen deck, a plurality of spring assemblies connecting the screen deck to the support frame, and a vibrating mechanism attached to the screen deck for imparting the vibratory motion to the screen  deck.  The dump truck receives the particle screener atop the dump body.
Patent CA-2381970-A1 (CA)
Title: Tissu non tisse ameliore a elongation elevee dans le sens travers (cd), et son procede de fabrication
Inventor: KAUSCHKE MICHAEL
IPC: D04H3/02
Filed: 2000-08-10
Abstract: L'invention concerne un tissu non tissé (40) constitué de fibres filées (20) dont la densité dans le tissu varie entre des bandes de densité relativement élevée et des bandes de densité relativement faible. Les bandes s'étendent sur la longueur du tissu dans le sens machine selon un motif alternant, les bandes de densité élevée étant séparées les unes des autres par les bandes de faible densité. Les bandes alternantes de densité élevée ou faible fournissent au tissu un pourcentage d'élongation plus élevé dans le sens travers (12) que dans le sens machine.
Patent CA-2383217-A1 (CA)
Inventor: CANFIELD WILLIAM M
IPC: C12N15/09
Filed: 2000-09-14
Abstract: L'invention concerne des enzymes GlcNac-phosphotransférase et phosphodiester .alpha.-GlcNAcase à voie de ciblage lysosomial, qui sont récupérées et utilisées pour produire des hydrolases lysosomiales fortement phosphorylées pouvant servir à traiter les maladies lysosomales. Les molécules d'acide nucléique codant pour les enzymes sont généralement incorporées dans des vecteurs d'expression qui sont utilisés pour transfecter des cellules hôtes qui expriment les enzymes. Les enzymes exprimées sont récupérées et utilisées pour traiter les hydrolases lysosomiales ayant des structures de mannose élevées. Les hydrolases lysosomiales résultantes comportent des oligosaccharides liés à l'asparagine qui sont fortement phosphorylés avec du mannose-phosphate. Les hydrolases lysosomiales fortement phosphorylées sont rapidement absorbées dans la cellule et dans le lysosome au cours de thérapies de substitution.
Patent CA-2383631-A1 (CA)
Inventor: CISE DAVID M
IPC: A61M16/04
Filed: 2000-09-07
Abstract: A flexible multiple port adaptor has an adaptor body (100) which includes a distal portion (110) defining a distal channel (114) and a proximal portion (122) defining a first proximal channel (126) and a second proximal channel (130). At least one of the first and second proximal channels is normally disposed out of alignment with the distal channel (114). However, because the adaptor body (100) is flexible, the adaptor body (100) may be manipulated so that channel(s) (126, 130) which are out of alignment with the distal channel (114) may be placed into alignment with the distal channel (114) so that a medical instrument can be advanced through the channels without bending the medical instrument.
Patent CA-2385928-A1 (CA)
Inventor: HANUS LUMIR
IPC: C07C69/24
Filed: 2000-10-30
Abstract: The invention provides novel pharmaceutical compositions comprising as the active ingredient 4-phenyl pinene derivatives which are specific for the peripheral cannabinoid receptors. In particular, the compounds of the invention binds efficiently to CB2 but do not bind to CB1. The compounds show no activity in behavioral tests in mice which together have been shown to be specific for tetrahydrocannabinol (THC)- type activity in the central nervous system mediated by CB1 but reduce blood pressure, block intestinal mobility, and elicit anti-inflammatory and peripheral analgetic activity. The invention also relates to methods of treating, preventing, or managing hypertension, inflammation, pain, gastrointestinal diseases, autoimmune diseases, and tumors with the compounds of the invention.
Patent CA-2388895-A1 (CA)
Title: A billing system and method for determining transportation charges for packages
Inventor: COOPER GORDON C
IPC: G06Q30/04
Filed: 2002-06-04
Abstract: A billing system for determining package transportation charges. The billing system includes a reader to read a package identifier associated with said package and the reader generates a package identifier signal and transmits the same to a microprocessor. The billing system also includes a package sizer having a plurality of non-contact optical sensors located along each of an x, y and z axis, where each optical sensor is in a known position. The sensors are oriented relative to the conveyor so that packages passing over the sensors are detected by the sensors and produce a signal correlated to said package size. Also provided is a microprocessor to receive and correlate said package size and identifier signals, and to determine an appropriate shipping charge based upon the same. A weigh scale may also be incorporated into the system. A method of determining a transportation charge is also comprehended, which includes a self-diagnostic initialization procedure.
Patent CA-2389430-A1 (CA)
Inventor: YU PEIWEN
IPC: C12Q1/68
Filed: 2000-11-16
Abstract: La présente invention concerne de nouveaux polypeptides, acides nucléiques et molécules liées qui possèdent un effet sur le cycle cellulaire ou sont liées à celui-ci. L'invention se rapporte également à des vecteurs et à des cellules hôtes renfermant ces séquences nucléotidiques, à des molécules de polypeptides chimères renfermant les polypeptides de l'invention fusionnés avec des séquences de polypeptides hétérologues, à des anticorps qui se lient aux polypeptides de l'invention et à des procédés de production des polypeptides de l'invention. L'invention concerne en outre des procédés permettant d'identifier de nouvelles compositions qui interviennent comme médiateurs dans la bioactivité du cycle cellulaire, et l'utilisation de ces compositions dans le diagnostic et le traitement de maladies.
Patent CA-2389750-A1 (CA)
Title: Hydrogenation of hydrocarbon resins
Inventor: DIJKSTRA WILLEM
IPC: C08F8/04
Filed: 2000-11-01
Abstract: The invention is directed to a process for the hydrogenation of hydrocarbon resins in the presence of a precious metal catalyst, wherein the hydrogenati on is performed in the additional presence of at least one metal oxide, capable  of reacting with sulfide and/or halogen.
Patent CA-2392706-A1 (CA)
Inventor: DRISCOLL KEVIN
IPC: G06F7/58
Filed: 2000-12-01
Abstract: L'invention concerne un générateur rapide de nombres pseudo-aléatoires, qui peut être utilisé dans divers systèmes tels qu'un système cryptographique à algorithme de chiffrement en continu ou un système de simulation de Monte Carlo. Le générateur comprend un registre à décalage à rebouclage linéaire (LFSR) comportant un état contenu dans N éléments de mémoire stockant N bits de données binaires ; ces dernières sont séparées en w mots de longueur M. Au moins deux sources de dérivation fournissent des données binaires, chaque source de dérivation comportant un nombre de bits qui est un multiple de M. Le LFSR inclut également une fonction de rebouclage linéaire couplée à des sources de dérivation et fournissant une valeur temporaire qui est une fonction linéaire, telle que OU exclusif au niveau du bit, des données binaires fournies par les sources de dérivation. L'état de LFSR est avancé par décalage des données binaires dans les éléments de mémoire selon un multiple de M bits, et fournit la valeur temporaire pour remplir les éléments de stockage, qui, autrement, seraient vides en raison du décalage.
Patent CA-2393058-A1 (CA)
Title: Method of manufacturing a four color modular printhead
Inventor: JACKSON GARRY RAYMOND
IPC: B41J2/235
Filed: 2000-12-07
Abstract: A method of manufacturing a printhead assembly (10) includes selecting a micromolding sub-assembly (24), the sub-assembly (24) comprising a printhead chip (18), a flexible printed circuit board (PCB, 54) and a micromolding (26). The micro-molding sub-assembly (24) is attached to a cover molding (28) to form a print module (12). An ink reservoir sub-assembly (16) is formed and a plurality of the printhead modules (12) are attached to the ink reservoir sub-assembly (16) in end-to-end relationship.  Ink is charged into the reservoir sub-assembly (16) and the completed assembly is tested.
Patent CA-2393367-A1 (CA)
Title: Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b)
Inventor: SCHEIGETZ JOHN
IPC: A61P25/28
Filed: 2000-12-21
Abstract: The invention encompasses the novel class of compounds represented by formul a (I), which are inhibitors of the PTP-1B enzyme. The invention also encompass es pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and conditions related to diabetes.
Patent CA-2397957-A1 (CA)
Inventor: SAWAN MOHAMAD
IPC: A61N1/36
Filed: 2001-01-31
Abstract: The present invention relates to lower urinary dysfunctions and more particularly to an electronic stimulator implant and method to improve bladder voiding and prevent bladder hyperreflexia. There is provided an electronic stimulator implant for which comprises a tonicity signal generator generating a tonicity signal which prevents bladder hyperreflexia combined with a voiding signal generator generating a voiding signal for voiding the bladder. The implant is connected to an end of an electrode, and the second end thereof is connected to a sacral nerve. When the voiding key (or switch) is activated, the voiding signal is generated which activates detrusor muscle contraction, causing bladder voiding. The voiding may be achieved without dyssynergia, by activating detrusor muscle contraction without activating external urethral sphincter contraction. The tonicity signal may he provided intermittently.      The implant may be activated by a manually activated external controller.
Patent CA-2399918-A1 (CA)
Title: Water containing soluble fiber
Inventor: STILLMAN SUZANNE JAFFE
IPC: A23L1/308
Filed: 2001-02-22
Abstract: A water-like fluid containing safe water and a significant quantity of soluble dietary fiber. The resulting solution is generally optically clear and has physical properties similar to potable water. The fluid is intended as a replacement for bottled, or other water, as a means to ensure proper hydration. Depending on the soluble fiber used the fluid is either non-caloric or extremely low in calories. The amount of soluble fiber is adjusted to a specific amount of water so that consumption of an adequate amount of fluid ensures hydration (e.g., eight 8 oz. glasses per day) will also providing an optimal amount of dietary fiber. This is particularly valuable in stressed situations where the diet may not provide adequate fiber without supplementation. The constant metered supply of fiber provided throughout the day is preferable to, and more convenient than, "bolus" administration of fiber through laxatives, etc. Additionally, the constant presence of soluble fiber in the digestive tract provides the known beneficial effects of moderating the postprandial increase in blood glucose, modulating serum lipid levels, and suppressing appetite.